Welcome to our dedicated page for Wesana Health Holdings news (Ticker: WSNAF), a resource for investors and traders seeking the latest updates and insights on Wesana Health Holdings stock.
Wesana Health Holdings Inc. (WSNAF) has issued a series of news releases that trace its evolution from a data-driven life sciences company focused on mental health drug development and care delivery to a company that has exited its psychedelics business and is seeking new opportunities. The news flow provides context on its strategic decisions, asset sales, governance changes, and financing activities.
Earlier announcements describe Wesana Health’s work on SANA-013, a lead drug development candidate for Major Depressive Disorder and related indications, including preclinical animal study results and feedback from a pre-IND meeting with the U.S. Food and Drug Administration. Other releases outline the company’s former care delivery assets, such as clinic management operations in the greater Chicago area, a clinical software platform, and a professional community focused on the clinical use of psychedelics.
Subsequent news highlights strategic reviews and completed transactions, including the sale of clinic management services organization assets and the sale of SANA-013 intellectual property and related assets to another life sciences company. These items are presented alongside information on private placements, short-term financing, and efforts to streamline operations and reduce expenses.
More recent communications note changes to the board of directors and state that Wesana Health discontinued its psychedelics business and disposed of the related assets in 2023, and is now looking for new business opportunities. Readers following WSNAF news can use this page to review historical announcements about its drug development activities, asset divestitures, governance updates, and capital markets transactions.
Wesana Health Holdings (CSE: WESA; OTCQB: WSNAF) has announced a milestone of over 4,000 ketamine treatments administered through its Wesana Clinics for mental health issues including depression and PTSD. CEO Daniel Carcillo emphasized the urgent need for effective mental health treatments. The clinics, located in Oak Brook and Downtown Chicago, operate under the guidance of Dr. Abid Nazeer. Additionally, Wesana Solutions, a proprietary patient management platform, is currently in beta testing, aimed at enhancing treatment efficacy.
Wesana Health Holdings Inc. (CSE: WESA; OTCQB: WSNAF) announced that CEO Daniel Carcillo will participate in the KCSA Psychedelics Investor Conference on October 13-14, 2021. Carcillo is scheduled to present live on October 14 at 3:30 pm EST. The conference will offer an interactive platform for publicly-traded companies to connect with investors. Wesana focuses on innovative approaches to neurological health, including psychedelic medicines. Interested attendees can register for the conference here.
Wesana Health Holdings Inc. (CSE: WESA; OTCQB: WSNAF) has been included in the AdvisorShares Psychedelics ETF (PSIL), which invests in life sciences and biotech firms focused on psychedelic compounds. This inclusion highlights Wesana’s advancements in neurological health research and signals increased visibility for the company.
Chad Bronstein, Executive Chairman, expressed pride in this recognition, viewing it as validation of Wesana's impact in the psychedelics sector and a step toward enhancing shareholder engagement.
Wesana Health Holdings (CSE: WESA; OTCQB: WSNAF) has committed $1.5 million to assess the viability of MDMA-assisted therapy for treating traumatic brain injury (TBI). This funding will support the Multidisciplinary Association for Psychedelic Studies (MAPS) in evaluating the unmet need for TBI treatment and exploring a joint venture. With over 6.2 million Americans suffering from chronic TBI-related disabilities, this collaboration aims to accelerate research timelines and enhance access to MDMA treatments, benefiting those affected by TBI.
Wesana Health Holdings Inc. (CSE: WESA; OTCQB: WSNAF) announced the closing of its acquisition of Psychedelitech Inc. on September 8, 2021. This acquisition enhances Wesana's capabilities in neurological health through its new subsidiaries: Wesana Clinics, focused on integrated mental health care; Wesana Solutions, a clinical SaaS platform; and PsyTech Connect, a community for psychedelic therapy. The company is also pursuing a listing on a US national exchange to expand its market presence.
Wesana Health Holdings has appointed Dr. Rachel Yehuda, a leading psychopharmacology researcher, to its Scientific Advisory Board. Dr. Yehuda brings over 30 years of experience in trauma research, particularly in psychedelic-assisted therapies. She will guide Wesana’s research efforts in treating traumatic brain injury (TBI) through innovative psychedelic approaches. The leadership believes her expertise will enhance Wesana’s strategic goals in developing treatments for neurological conditions.
Wesana Health Holdings Inc. announces the appointments of four new board members: Dr. Robert Koffman, Ian Burnstein, Mitch Kahn, and George Steinbrenner IV, enhancing its strategic and leadership capabilities. Dr. Koffman, a former naval officer, brings extensive experience in PTSD and traumatic brain injury research. Burnstein offers investment and entrepreneurial insights, while Kahn has a strong background in the cannabis sector. Steinbrenner IV is known for his entrepreneurial ventures. This diverse team aims to propel Wesana towards becoming a leader in neurological health treatment.
Wesana Health Holdings (CSE: WESA; OTCQB: WSNAF) has initiated functional animal studies to investigate the impact of a psilocybin-based regimen on locomotor activity, anxiety, and depression. Preliminary results from the locomotor study suggest no adverse drug interactions. Additionally, a Pilot Study on traumatic brain injury (TBI) patients has concluded, paving the way for a Pivotal Study starting August 2021. Results from the anxiety and depression study are expected by early Q4 2021, emphasizing Wesana's commitment to treating neurological health issues.
Wesana Health Holdings has achieved a significant milestone by receiving approval to trade on the OTCQB Venture Market under the ticker symbol WSNAF, effective August 2, 2021. This move will enhance visibility and liquidity for US investors, allowing transactions in US dollars. The company is focused on developing innovative treatments for neurological health, particularly through psychedelic medicines. Additionally, Wesana has gained eligibility from the DTC for easier electronic trading and settlement in the US markets.